{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T04:06:56Z","timestamp":1792123616636,"version":"4.4.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["atherosclerosis-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1016\/j.atherosclerosis.2013.07.056","type":"journal-article","created":{"date-parts":[[2013,8,21]],"date-time":"2013-08-21T05:45:43Z","timestamp":1377063943000},"page":"373-380","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":138,"title":["Lipid lowering in healthy volunteers treated with multiple doses of MGL-3196, a liver-targeted thyroid hormone receptor-\u03b2 agonist"],"prefix":"10.1016","volume":"230","author":[{"given":"Rebecca","family":"Taub","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malorie","family":"Chabot-Blanchet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha J.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Reeves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Claude","family":"Guertin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Claude","family":"Tardif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.atherosclerosis.2013.07.056_bib1","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1161\/CIRCULATIONAHA.108.838466","article-title":"Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals","volume":"120","author":"Waters","year":"2009","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.atherosclerosis.2013.07.056_bib2","doi-asserted-by":"crossref","first-page":"858","DOI":"10.7326\/0003-4819-150-12-200906160-00009","article-title":"Narrative review: statin-related myopathy","volume":"150","author":"Joy","year":"2009","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2013.07.056_bib3","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2337\/diacare.14.3.173","article-title":"Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease","volume":"14","author":"DeFronzo","year":"1991","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2013.07.056_bib4","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/ncpendmet1066","article-title":"Dyslipidemia in type 2 diabetes mellitus","volume":"5","author":"Mooradian","year":"2009","journal-title":"Nat Clin Pract Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.atherosclerosis.2013.07.056_bib5","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.2337\/dc06-0455","article-title":"Influence of hepatic steatosis (fatty liver) on severity and composition of dyslipidemia in type 2 diabetes","volume":"29","author":"Toledo","year":"2006","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2013.07.056_bib6","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1210\/en.2003-0973","article-title":"Effects of the thyroid hormone receptor agonist GC-1 on metabolic rate and cholesterol in rats and primates: selective actions relative to 3,5,3'-triiodo-L-thyronine","volume":"145","author":"Grover","year":"2004","journal-title":"Endocrinology"},{"issue":"17","key":"10.1016\/j.atherosclerosis.2013.07.056_bib7","doi-asserted-by":"crossref","first-page":"10067","DOI":"10.1073\/pnas.1633737100","article-title":"Selective thyroid hormone receptor-beta activation: a strategy for reduction of weight, cholesterol, and lipoprotein (a) with reduced cardiovascular liability","volume":"100","author":"Grover","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"29","key":"10.1016\/j.atherosclerosis.2013.07.056_bib8","doi-asserted-by":"crossref","first-page":"10297","DOI":"10.1073\/pnas.0504379102","article-title":"Selective thyroid receptor modulation by GC-1 reduces serum lipids and stimulates steps of reverse cholesterol transport in euthyroid mice","volume":"102","author":"Johansson","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2013.07.056_bib9","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1089\/105072502760143935","article-title":"Clinical and experimental studies on the use of 3,5-diiodothyropropionic acid, a thyroid hormone analogue, in heart failure","volume":"12","author":"Morkin","year":"2002","journal-title":"Thyroid"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2013.07.056_bib10","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/nrd2830","article-title":"Thyroid hormone mimetics: potential applications in atherosclerosis, obesity and type 2 diabetes","volume":"8","author":"Baxter","year":"2009","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2013.07.056_bib11","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.abb.2010.06.021","article-title":"Thyroid and bone","volume":"503","author":"Gogakos","year":"2010","journal-title":"Arch Biochem Biophys"},{"issue":"15","key":"10.1016\/j.atherosclerosis.2013.07.056_bib12","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1161\/CIRCULATIONAHA.106.678326","article-title":"Thyroid disease and the heart","volume":"116","author":"Klein","year":"2007","journal-title":"Circulation"},{"issue":"39","key":"10.1016\/j.atherosclerosis.2013.07.056_bib13","doi-asserted-by":"crossref","first-page":"15490","DOI":"10.1073\/pnas.0702759104","article-title":"Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index","volume":"104","author":"Erion","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2013.07.056_bib14","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1073\/pnas.0705286104","article-title":"The thyroid hormone mimetic compound KB2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humans","volume":"105","author":"Berkenstam","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"10.1016\/j.atherosclerosis.2013.07.056_bib15","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0905633","article-title":"Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia","volume":"362","author":"Ladenson","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2013.07.056_bib16","series-title":"\u201cKaro Bio terminates the eprotirome Program\u201d Karo Bio February 14","author":"Bengsston","year":"2012"},{"key":"10.1016\/j.atherosclerosis.2013.07.056_bib17","series-title":"Discovery and development of MGL-3196, a liver-directed thyroid hormone beta agonist for the treatment of hypercholesterolemia\/dyslipidemia and hypertriglyceridemia","author":"Kelly","year":"2013"},{"key":"10.1016\/j.atherosclerosis.2013.07.056_bib18","doi-asserted-by":"crossref","first-page":"S1095","DOI":"10.1161\/circ.120.suppl_18.S1095-c","article-title":"VIA-3196, a liver-directed thyroid beta agonist for treating cardiometabolic disease","volume":"120","author":"Taub","year":"2009","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2013.07.056_bib19","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2217\/clp.09.85","article-title":"Mechanisms and clinical implications of hepatocyte lipoapoptosis","volume":"5","author":"Cazanave","year":"2010","journal-title":"Clin Lipidol"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2013.07.056_bib20","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1136\/ewjm.172.2.102","article-title":"How medications affect thyroid function","volume":"172","author":"Dong","year":"2000","journal-title":"West J Med"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2013.07.056_bib21","first-page":"306","article-title":"Peripheral metabolism of thyroid hormones: a review","volume":"5","author":"Kelly","year":"2000","journal-title":"Altern Med Rev"},{"issue":"10","key":"10.1016\/j.atherosclerosis.2013.07.056_bib22","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1172\/JCI29812","article-title":"Deiodinases: implications of the local control of thyroid hormone action","volume":"116","author":"Bianco","year":"2006","journal-title":"J\u00a0Clin Invest"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2013.07.056_bib23","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1056\/NEJMoa1110296","article-title":"A\u00a0mutation in the thyroid hormone receptor alpha gene","volume":"366","author":"Bochukova","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2013.07.056_bib24","first-page":"854","article-title":"Multiphasic thyrotropin responses to thyroid hormone administration in man","volume":"80","author":"Spencer","year":"1995","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.atherosclerosis.2013.07.056_bib25","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1210\/en.2012-1572","article-title":"Thyroid hormone reduces cholesterol via a non-LDL receptor-mediated pathway","volume":"153","author":"Goldberg","year":"2012","journal-title":"Endocrinology"},{"issue":"27","key":"10.1016\/j.atherosclerosis.2013.07.056_bib26","first-page":"2677","article-title":"Sex hormone-binding globulin and risk of type 2 diabetes","volume":"361","author":"Semple","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2013.07.056_bib27","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1172\/JCI38793","article-title":"Resistance to thyroid hormone is associated with raised energy expenditure, muscle mitochondrial uncoupling, and hyperphagia","volume":"120","author":"Mitchell","year":"2010","journal-title":"J\u00a0Clin Invest"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2013.07.056_bib28","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/hep.22572","article-title":"Reduction of hepatic steatosis in rats and mice after treatment with a liver-targeted thyroid hormone receptor agonist","volume":"49","author":"Cable","year":"2009","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2013.07.056_bib29","first-page":"913","article-title":"A\u00a0comparative study of thyroid hormone levels in diabetic and non-diabetic patients","volume":"39","author":"Islam","year":"2008","journal-title":"Southeast Asian J Trop Med Public Health"},{"key":"10.1016\/j.atherosclerosis.2013.07.056_bib30","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1152\/ajpendo.00573.2012","article-title":"Thyroid hormone receptor-beta agonists prevent hepatic steatosis in fat-fed rats but impair insulin sensitivity via discrete pathways","volume":"305","author":"Vatner","year":"2013","journal-title":"Am J Physiol Endocrinol Metab"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915013004620?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915013004620?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T22:59:25Z","timestamp":1715900365000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915013004620"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S0021915013004620"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2013.07.056","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipid lowering in healthy volunteers treated with multiple doses of MGL-3196, a liver-targeted thyroid hormone receptor-\u03b2 agonist","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2013.07.056","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}